Treatment Patterns and Survival among Adult Patients with Advanced Soft Tissue Sarcoma: A Retrospective Medical Record Review in the United Kingdom, Spain, Germany, and France

Table 5

Five most commonly prescribed first-line treatment regimens by histologic category.

Histologic category and treatment	N (%)
Nonuterine leiomyosarcoma ( )
Doxorubicin	67 (46.5)
Doxorubicin + ifosfamide^a	24 (16.7)
Docetaxel + gemcitabine	15 (10.4)
Ifosfamide^a	9 (6.3)
Dacarbazine + doxorubicin + ifosfamide^a	5 (3.5)
Uterine leiomyosarcoma ( )
Docetaxel + gemcitabine	33 (38.8)
Doxorubicin + ifosfamide^a	15 (17.6)
Doxorubicin	14 (16.5)
Trabectedin	7 (8.2)
Carboplatin + paclitaxel	2 (2.4)
Fibroblastic/myofibroblastic sarcoma ( )
Doxorubicin	32 (41.0)
Doxorubicin + ifosfamide^a	13 (16.7)
Ifosfamide^a	6 (7.7)
Epirubicin + ifosfamide^a	6 (7.7)
Dacarbazine + ifosfamide^a	4 (5.1)
Liposarcoma ( )
Doxorubicin	65 (61.9)
Doxorubicin + ifosfamide^a	15 (14.3)
Docetaxel + gemcitabine	3 (2.9)
Docetaxel	3 (2.9)
Trabectedin	3 (2.9)
Vascular sarcoma ( )
Paclitaxel	28 (35.4)
Doxorubicin	18 (22.8)
Doxorubicin + ifosfamide^a	7 (8.9)
Ifosfamide^a	4 (5.1)
Docetaxel + gemcitabine	3 (3.8)
Rhabdomyosarcoma ( )
Doxorubicin	34 (39.5)
Doxorubicin + ifosfamide^a	19 (22.1)
Ifosfamide^a	5 (5.8)
Pazopanib	5 (5.8)
Docetaxel + gemcitabine	3 (3.5)
Synovial sarcoma ( )
Doxorubicin	23 (48.9)
Doxorubicin + ifosfamide^a	7 (14.9)
Ifosfamide^a	4 (8.5)
Docetaxel + gemcitabine	3 (6.4)
Paclitaxel	3 (6.4)
Others/NOS ( )
Doxorubicin	77 (42.1)
Doxorubicin + ifosfamide^a	53 (29.0)
Docetaxel + gemcitabine	9 (4.9)
Epirubicin + ifosfamide^a	7 (3.8)
Dacarbazine + doxorubicin + ifosfamide^a	4 (2.2)

NOS: not otherwise specified; Denominators for the percentages are patients who received one of the five most commonly prescribed first-line regimens within each histologic category; ^amesna was always coadministered with ifosfamide.